Evidence map›Paper›PMID 33972060›Full record

ArticleClinics in dermatology

Is the BCG vaccine a useful tool against COVID-19?

Galina Zhelezova, Valeria Mateeva, Grisha Mateev

Open access · greenAbstract read
In one paragraph

Article in Clinics in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Galina ZhelezovaDepartment of Biology, Medical Genetic, and Microbiology, Medical Faculty, Medical University, Sofia, Bulgaria.
Valeria MateevaDepartment of Dermatology and Venereology, Medical Faculty, Medical University, Sofia, Bulgaria.
Grisha MateevDepartment of Dermatology and Venereology, Medical Faculty, Medical University, Sofia, Bulgaria. Electronic address: grisha_mateev@yahoo.com.
Medical University of Sofia · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Bacillus Calmette-Guérin (BCG) vaccine has been used since 1921 initially for protection against tuberculosis. BCG acts through stimulation of cell-mediated adaptive immunity with activation of the Th1 cells and production of interferon gamma. Additionally, it is able to stimulate the immune system in a nonspecific manner, which results in effectiveness of the BCG against non-mycobacterial infections and in some malignant, autoimmune, and inflammatory diseases. Recently, its potential use in the fight against the coronavirus disease 2019 (COVID-19) pandemic has been suggested. This is based upon the concept of BCG-induced trained innate immunity-a memory-like response of the innate immune system that can realize greater protection in case of re-infection. This hypothesis represents a milestone in the potential use of the BCG vaccine in the fight with the novel coronavirus.

Indexed as

Adjuvants, ImmunologicBCG VaccineCOVID-19HumansImmunity, InnateSARS-CoV-2Adjuvants, ImmunologicBCG Vaccine

Identifiers

PMID33972060
PMCPMC7836423
OpenAlexW3112775024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.